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We aimed to study trends in gender-related differences in incidence, and prevalence for
long-term oxygen therapy due to chronic obstructive pulmonary disease. Another aim was
to study survival after onset of oxygen therapy.
Prospectively followed were 5689 Swedish patients, who were prescribed oxygen therapy
because of chronic obstructive pulmonary disease from 1987 to 2000.
The annual incidence of women starting oxygen therapy increased more rapidly than that
in men. In 2000, 7.6 per 100,000 women started treatment compared with 7.1 in men. The
frequency of ever smoking in Sweden in the age group receiving oxygen, i.e. age 65–84
years, was 36.4% in women and 65.0% in men, indicating that women ran a higher risk of
developing an oxygen-requiring chronic hypoxaemia. An increase in women requiring
oxygen therapy is predicted due to the increase in smoking frequency in young and middle-
aged women and it is estimated that about 70% of Swedish patients on oxygen in 2026 will
be women, with an estimated prevalence of 61 per 100,000.
In conclusion, the incidence and prevalence for long-term oxygen therapy increases more
rapidly among women than in men. This is probably due to the increased frequency of
smoking in women compared with men and a higher susceptibility to develop severe
hypoxaemia in women. The survival is better in women with long-term oxygen therapy
than in men.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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.Umu.Se (K.A. Franklin).Introduction
Chronic obstructive lung disease is the fifth largest cause of
death worldwide.1 Smoking is the most common cause of
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Table 1 Prevalence of ever smoking in Sweden in 2001
according to Statistics Sweden.4
Age Ever smoking (%)
Men Women
16–24 23.5 30.1
25–34 33.6 37.9
35–44 43.4 52.4
45–54 63.9 59.5
55–64 69.9 54.0
65–74 64.1 41.8
75–84 66.3 30.3
Long-term oxygen therapy in COPD 1507chronic obstructive pulmonary disease. In global terms, 47%
of men and 12% of women smoke, corresponding to
approximately one billion men and 250 million women.2,3
The prevalence of smoking among women has increased in
recent decades and today more women than men smoke in
some countries, including Sweden.4
Long-term oxygen therapy improves survival in patients
with severe hypoxaemia due to chronic obstructive pulmon-
ary disease.5–7 Many studies of oxygen therapy are fairly old
and only a few of the patients included in them were
women.5–9 Recent studies do, however, include a larger
fraction of women.10,11
We aimed to study trends in gender-related differences in
annual incidence, and prevalence for long-term oxygen
therapy due to chronic hypoxia from chronic obstructive
pulmonary disease and to predict the need for oxygen
therapy in the future. Another aim was to study survival
after onset of oxygen therapy.Methods
Eligible for inclusion were all the Swedish women and men
aged 18 and above who received oxygen therapy from
1 January 1987 to 31 December 2000 due to severe
hypoxaemia caused by chronic obstructive pulmonary dis-
ease. All the departments of respiratory medicine and all
the other clinics prescribing oxygen in all 24 Swedish
counties agreed on the national guidelines from the Swedish
Society of Respiratory Medicine for long-term oxygen
therapy, and prospectively register patients starting treat-
ment from 1 January 1987 in a Swedish Oxygen Register.12–14
The national guidelines for oxygen therapy were arterial
oxygen tension (PaO2) of p7.3 kPa for at least three weeks,
including optimum medical therapy, or a PaO2 of less than
8 kPa, with signs of right heart failure, or haematocrit of
over 50%.12,13 It was stated that oxygen should be delivered
during a minimum of 16 h a day and preferably during 24 h.
Excluded were patients who had been registered in centres
from four of the 24 Swedish counties, since these centres
withdrew from the study during some years, because of a
shortage of staff. Sweden had 8.3 million inhabitants in 1987
and 8.9 million in 2000. The population in the participating
counties was 7.6 million in 1987 and 8.0 million in 2000.
Arterial blood gas tensions when breathing air and
oxygen, smoking history, peripheral oedema, forced expira-
tory volume in 1 s and forced vital capacity were registered
at the start of treatment. One-year follow-up data included
reasons for withdrawal. The vital status until 31 December
2003 and the dates of death were obtained from the Causes
of Death Register at the Swedish National Board of Health
and Welfare.
The predicted incidence and prevalence of the need for
oxygen therapy were calculated from the frequency of ever
smoking in Sweden in 2001 in different age groups (Table 1).4
It was assumed that the age at the start of treatment for
men and women would be the same in the future as in 2000
and that the quotient between the prevalence and
incidence would be the same as from 1987 to 2000.
Every regional ethics committee in Sweden, i.e. the
ethics committees in Stockholm, Go¨teborg, Lund, Uppsala,
Umea˚, Linko¨ping and O¨rebro, the National Board of Healthand Welfare and the Data Inspection Board approved the
study. All the patients gave their informed consent.
Statistical analysis
Chi-squared tests were used for categorical data and t-tests
were used for continuous data. Age-adjusted analyses of
category variables were performed using logistic regression.
Linear regression analyses were used for adjustments of age
and other confounders in time-trend analyses of continuous
variables. Time to death was analysed using Cox regression
and adjusting for age. A significance level of 5% and a
confidence level of 95% were used. Statistical analyses were
performed with SPSS (version 11.5) and Stata (version 8.2).
Results
A total of 5689 patients were included in the final analysis,
2894 women and 2795 men. The women were 6678 years
old at the start of the study in 1987 and 7379 years old in
2000. The men were slightly older than women: they were
6779 years old in 1987 (po0.001) and 7478 years old in
2000 (po0.001). Seventy-three percent of the women and
70% of the men had an oxygen tension (PO2) of p7.3 kPa at
the onset of oxygen therapy. Three hundred and ninety-four
patients were excluded since they were registered in the
four counties that withdrew from the study during some
years. They did not differ in age and gender from the
included patients.
Mean arterial PaO2 was slightly lower and mean PaCO2 was
higher in women than in men when starting oxygen therapy
(po0.001) (Table 2). Mean PaCO2 at the start of treatment
gradually decreased in men from 1987 to 2000 (po0.001),
but it remained stable in women. The annual number of
women starting oxygen therapy increased from 2.0/100,000
in 1987 to 7.6/100,000 in 2000 (po0.001), while that of men
rose from 2.8/100,000 in 1987 to 7.1/100,000 in 2000
(po0.001) (Fig. 1). The annual incidence was higher in
women than in men after 1997. The prevalence of women on
oxygen increased more rapidly than that of men: 58% of the
subjects using oxygen in 2000 were women (Fig. 2). The
prevalence increased from 5.5/100,000 women in 1986 to
26.5/100,000 women in 2000 (po0.001), while that in men
rose from 5.7/100,000 to 19.3/100,000 (po0.001).
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Table 2 Patient characteristics at start of treatment.
Women n ¼ 2894 Men n ¼ 2795 p–value
Age (years) 7079 7279 o 0.001
PaO2 (kPa) 6.671.0 6.770.9 o 0.001
PaCO2 (kPa) 6.671.2 6.171.2 o 0.001
PaO2 (oxygen) (kPa) 9.071.1 9.071.2 0.95
PaCO2 (oxygen) (kPa) 6.971.2 6.471.2 o 0.001
FEV1 (litres) 0.670.3 1.070.5 o 0.001
FVC (litres) 1.470.5 2.170.9 o 0.001
Peripheral oedema (%) 58 52 o0.001
Smoking history (%) o 0.001*
Current 4 3
Past 85 90
Never 11 6
Values are presented in percent or as the means7SD. PaO2: arterial oxygen tension; PaO2 (oxygen): arterial oxygen tension when
breathing oxygen; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. * The p-value refers to the whole 2 3 table.
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Figure 3 Survival in men and women receiving long-term
oxygen therapy from 1987 to 2000.
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Figure 1 Annual incidence of men and women starting oxygen
therapy from 1 January 1987 to 31 December 2000.
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Figure 2 Annual prevalence of men and women starting
oxygen therapy from 1 January 1987 to 31 December 2000.
K.A. Franklin et al.1508In 1987, 42% of patients were prescribed oxygen from
compressed gas cylinders and 58% were prescribed oxygen
from concentrators. The percentage of patients using
concentrators rose rapidly to 97% in 2000. Liquid oxygen
was prescribed in 2–3% of patients after 1993, when it was
introduced in Sweden. Slightly more men than women were
prescribed oxygen for X20 h a day, p ¼ 0.041. Two percent
of women were prescribed oxygen for less than 15 h a day,
60% for 15–17 h a day, 9% for 18–19 h a day and 29% for
20–24 h a day. In the case of men, 2% were prescribed
oxygen for less than 15 h a day, 59% for 15–17 h a day, 8% for
18–19 h a day and 31% for 20–24 h a day.
The median (first and third quartile) survival after the
start of treatment was 2.8 (2.6–2.9) years in women and 2.0
(1.9–2.1) years in men (Fig. 3). First year survival was 77%
(95% CI 75–79%) in women and 69% (95% CI 67–71%) in men.
The relative risk of death for males vs. females was 1.21
(95% CI 1.14–1.28) according to Cox regression adjusted for
age. Death was the reason for withdrawal from oxygen
therapy within one year of the start of treatment in 88% of
women and 91% of men. Improvement in oxygenation on
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Figure 4 Predicted annual incidence of men and women
starting oxygen therapy. Dashed lines indicate the predicted
values.
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Figure 5 Predicted annual prevalence of men and women
starting oxygen therapy. Dashed lines indicate the predicted
values.
Long-term oxygen therapy in COPD 1509room air, and non-compliant patients were other reasons for
withdrawal during the first year of treatment.
The frequency of ever smoking in Sweden in the age group
receiving oxygen, i.e. age 65–84 years, was 36.4% in women
and 65.0% in men in 2001.4 The incidence of long-term
oxygen therapy due to chronic obstructive pulmonary
disease was, however, slightly higher in women in
2000, indicating that women ran a 1.9 times higher risk
of developing oxygen-requiring respiratory insufficiency.
The frequency of ever smoking decreased with age among
women, while the opposite trend was seen in men (Table 1).
The predicted incidence and prevalence of long-term
oxygen therapy from 2006 to 2036 show an increase in
women, due to an increase in smoking frequency among
middle-aged women and a high risk of women who smoke
developing end-stage chronic obstructive pulmonary
disease requiring oxygen therapy. It is predicted that about
70% of patients on oxygen in 2026 will be women, with a
prevalence of 61 per 100,000 women and 29 per 100,000
men. The predicted incidence of women and men requiring
oxygen therapy is shown in Fig. 4 and the predicted
prevalence in Fig. 5.Discussion
The prevalence of subjects on long-term oxygen therapy
increased more rapidly in women than in men during the
study period due to a larger increase in women starting
oxygen treatment and improved survival among women. The
risk of women requiring long-term oxygen therapy was
almost twice as high as that among men when smoking
history was taken into consideration. Today, 58% of patients
on oxygen therapy are women and this female dominance
will probably increase in the near future due to many
middle-aged female smokers. The survival after treatment
start of oxygen therapy was significantly longer in women
than in men.
There are gender differences in airway behaviour over the
human life span and it has been suggested that smoking is
more deleterious for lung function in women than in men.15
The growth of lung function is slower in adolescent smoking
girls than in smoking boys and women who start to smoke in
childhood run a higher risk of a reduction in lung function
and airway disease later in life.16,17 Female smokers ran an
increased risk for chronic obstructive pulmonary disease,
and the loss of forced expiratory volume in 1 s per pack-year
of smoking is also slightly higher in women.18,19 We found no
study of gender differences in susceptibility to respiratory
insufficiency or the need for oxygen therapy. Since 1993, the
majority of Swedish smokers have been women, but the
percentage of ever-smokers was almost half as high in
women than in men at the age when oxygen was started in
the present study.4,20 Women also smoked fewer cigarettes a
day.4,20 In spite of this, we found that more women than
men started oxygen therapy due to chronic obstructive
pulmonary disease and those women were slightly younger
than men at the start of treatment. Our results indicate that
the risk of respiratory failure and long-term oxygen therapy
later in life is almost twice as high among female smokers
compared with males, which is a new finding. Our study does
not indicate that more women than men were treated
because doctors are more biased to treat women. In fact,
the opposite was found. The women in our study had a
higher PCO2, they were statistically more hypoxic, but
probably not clinically and they more frequently had
peripheral oedema than men at the start of treatment.
With few exceptions, chronic obstructive pulmonary
disease in the western world is due to smoking. The fall in
lung function is related to both pack-years of smoking and
age.19,21 We predicted the incidence and prevalence of
oxygen therapy in the next 30 years from the frequency of
ever smoking in different age groups in 2001. We suggest
that the need for oxygen therapy will be stable among men
but will increase in women in the near future due to an
increased risk of respiratory insufficiency and an increase in
smoking prevalence among young and middle-aged women.
Miyamoto et al. reported a survival of 5.270.2 years in
Japanese women and 4.870.2 years in men after the onset
of oxygen therapy.8 They included 12,714 subjects from
1212 institutions but excluded 60% of them in their analysis.
Only 25% of their patients were women. Chailleux et al.
reported a median survival of 3 years among 12,043
subjects.9 They included approximately 70% patients receiv-
ing oxygen therapy and only 16% of their patients were
women. Machado et al. followed 251 men and 184 women,
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K.A. Franklin et al.1510and observed a median survival of about 36 months and a
better survival among men.11 Crockett et al. followed 249
men and 256 women and reported an overall first year
survival of 75% and a median survival of 22 months in men
and of 28 months in females.10 A lower survival rate was
observed in the present patients compared with Miyamoto
et al., Chailleux et al., and Machado et al., as the median
survival was only 2.8 years in women and 2.0 years in men.
The survival of the present Swedish patients was, however,
close to Australian patients reported by Crockett et al.10 We
included 94% of patients receiving oxygen therapy during a
period of 14 years and 51% of them were women. The age,
sample size and indications for oxygen therapy were about
the same in all studies. Differences in patient selection
could still explain some of the differences in survival rate.
However, 63% of patients in the study by Miyamoto et al.
used oxygen for at least 20 h a day,8 while only 30% were
prescribed to use it for 20 h or more in the present study.
The ‘‘NOTT’’ study from 1980 found an increase in survival in
subjects who were told to use oxygen therapy continuously
for 24 h compared with those who were told to use it for 12 h
a day.6 The low survival in Sweden for both women and men
on oxygen therapy could therefore be due to the prescrip-
tion to use it for about 16 h a day in the majority of cases
and not for 20–24 h a day.
One limitation of the present study is that we predict the
need for long-term oxygen therapy in relation to ever
smoking, and that we do not take into account a possible
effect of increased smoking cessation which could lower the
estimated need for oxygen therapy in the future. We also
forecast the need for oxygen therapy during the next 35
years from only 15 years of observation and the absolute
values are probably not reliable at the end of the prediction
period.
The present study was undertaken in the best possible
circumstances. Sweden is a fairly small, well-organised
country and the economic situation for most inhabitants,
including women, is good. The health care system is
organised in counties and all the hospitals and primary care
centres are either owned or supported by the county
council. The medical service, including equipment for
long-term oxygen therapy, was free and no changes in
management guidelines or reimbursement for long-term
oxygen therapy occurred after 1986. Only doctors specialis-
ing in respiratory medicine prescribed oxygen and it was
impossible to purchase oxygen equipment outside the
medical care system during the study period. Sweden has
very good official statistics relating to medical diagnoses,
treatments and causes of deaths. American and European
guidelines for starting long-term oxygen therapy are still the
same as in the present study.22 All centres and all doctors
prescribing oxygen took part in the present prospective
study, with the exception of centres in four counties in
certain years because of a shortage of staff. Around 9% of
the population lived in these four counties and excluded
patients did not differ in age and gender from included
patients. The exclusion is regarded as being of minor
relevance without any chance of affecting the present
results.
Patients starting oxygen therapy in Sweden today differ
from patients constituting the evidence of treatment and in
previous large follow-up studies of mortality.5,6,8,9 In themajority of cases, they are women. The number of disabled
women requiring continuous oxygen therapy will increase
still further, not only in Sweden but probably also in global
terms, as smoking has increased among women and the
tobacco industry is marketing cigarettes to young women in
most countries.23,24
In conclusion, the incidence and prevalence for long-term
oxygen therapy increase more rapidly among women than in
men. This is probably due to the increased frequency of
smoking in women compared with men and a higher
susceptibility to develop severe hypoxaemia in women.
The survival during long-term treatment of oxygen therapy
is better in women than in men. There is an obvious risk of a
large increase in a near future in the number of women
requiring oxygen therapy.Acknowledgements
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